Monoclonal antibodies in treatment of multiple sclerosis

Summary Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti‐alpha4‐integrin mAb natalizumab in 2004 and 2...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental immunology 2014-03, Vol.175 (3), p.373-384
Main Authors: Rommer, P. S., Dudesek, A., Stüve, O., Zettl, U.K.
Format: Article
Language:English
Subjects:
alemtuzumab
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
daclizumab
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Medical research
Multiple sclerosis
Multiple Sclerosis - drug therapy
natalizumab
Review
rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti‐alpha4‐integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing–remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing–remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.
ISSN:0009-9104
1365-2249
DOI:10.1111/cei.12197